DE69329425T2 - Dolastatin analog - Google Patents

Dolastatin analog

Info

Publication number
DE69329425T2
DE69329425T2 DE69329425T DE69329425T DE69329425T2 DE 69329425 T2 DE69329425 T2 DE 69329425T2 DE 69329425 T DE69329425 T DE 69329425T DE 69329425 T DE69329425 T DE 69329425T DE 69329425 T2 DE69329425 T2 DE 69329425T2
Authority
DE
Germany
Prior art keywords
dolastatin analog
dolastatin
analog
novel
chdcheco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329425T
Other languages
English (en)
Other versions
DE69329425D1 (de
Inventor
Andreas Haupt
Bernd Janssen
Kurt Ritter
Dagmar Klinge
Gerhard Keilhauer
Cynthia Romerdahl
Teresa Barlozzari
Xiao-Dong Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of DE69329425D1 publication Critical patent/DE69329425D1/de
Application granted granted Critical
Publication of DE69329425T2 publication Critical patent/DE69329425T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Window Of Vehicle (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69329425T 1992-12-16 1993-12-04 Dolastatin analog Expired - Fee Related DE69329425T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99130992A 1992-12-16 1992-12-16
PCT/EP1993/003410 WO1994013695A1 (en) 1992-12-16 1993-12-04 Dolostatin analog

Publications (2)

Publication Number Publication Date
DE69329425D1 DE69329425D1 (de) 2000-10-19
DE69329425T2 true DE69329425T2 (de) 2001-01-18

Family

ID=25537082

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329425T Expired - Fee Related DE69329425T2 (de) 1992-12-16 1993-12-04 Dolastatin analog

Country Status (24)

Country Link
US (1) US5502032A (de)
EP (1) EP0674652B1 (de)
JP (1) JPH08504415A (de)
CN (1) CN1057095C (de)
AT (1) ATE196296T1 (de)
AU (1) AU679479B2 (de)
BR (1) BR1100019A (de)
CA (1) CA2151953A1 (de)
CZ (1) CZ286752B6 (de)
DE (1) DE69329425T2 (de)
ES (1) ES2151921T3 (de)
FI (1) FI952961A0 (de)
HR (1) HRP931504B1 (de)
HU (1) HUT72067A (de)
IL (1) IL107987A (de)
NO (1) NO952366D0 (de)
NZ (1) NZ258882A (de)
PL (1) PL178766B1 (de)
RU (1) RU2132334C1 (de)
SG (1) SG67935A1 (de)
SI (1) SI9300661A (de)
TW (1) TW400335B (de)
WO (1) WO1994013695A1 (de)
ZA (1) ZA939389B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP2266607A3 (de) 1999-10-01 2011-04-20 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
EP1446110A2 (de) * 2001-10-16 2004-08-18 Structural Bioinformatics Inc. Organoschwefel-hemmer von tyrosinphosphatasen
AU2003218028A1 (en) 2002-03-08 2003-09-22 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
MXPA05012196A (es) * 2003-05-12 2006-02-08 Pfizer Prod Inc Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
EP1841749A1 (de) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
EP3498289A1 (de) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvalinverbindungen mit phenylalaninseitenkettenmodifikationen am c-terminus
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
CA2906784C (en) 2013-03-15 2023-02-28 The Centre For Drug Research And Development Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
MX2016008448A (es) 2013-12-27 2017-01-09 Zymeworks Inc Conjugados de var2csa-farmaco.
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3540495A1 (de) * 1985-11-15 1987-05-21 Merck Patent Gmbh Aminosaeurederivate
EP0249008B1 (de) * 1986-05-09 1993-09-15 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore
JP2714402B2 (ja) * 1988-07-13 1998-02-16 日清製粉株式会社 癌転移抑制剤
EP0357332A3 (de) * 1988-08-24 1991-07-31 Merck & Co. Inc. Renin-Inhibitoren zur Behandlung von AIDS durch Hemmung der HIV-Protease
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5138036A (en) * 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate

Also Published As

Publication number Publication date
NZ258882A (en) 1997-06-24
FI952961A (fi) 1995-06-15
ES2151921T3 (es) 2001-01-16
EP0674652A1 (de) 1995-10-04
US5502032A (en) 1996-03-26
CZ157595A3 (en) 1996-01-17
SG67935A1 (en) 1999-10-19
CN1095724A (zh) 1994-11-30
NO952366L (no) 1995-06-15
PL178766B1 (pl) 2000-06-30
CZ286752B6 (en) 2000-06-14
TW400335B (en) 2000-08-01
FI952961A0 (fi) 1995-06-15
DE69329425D1 (de) 2000-10-19
HRP931504A2 (en) 1997-02-28
RU95115135A (ru) 1997-06-10
AU5695994A (en) 1994-07-04
CA2151953A1 (en) 1994-06-23
JPH08504415A (ja) 1996-05-14
ATE196296T1 (de) 2000-09-15
PL309353A1 (en) 1995-10-02
ZA939389B (en) 1995-06-15
IL107987A0 (en) 1994-04-12
HU9501754D0 (en) 1995-08-28
RU2132334C1 (ru) 1999-06-27
BR1100019A (pt) 2000-07-25
HRP931504B1 (en) 2001-04-30
HUT72067A (en) 1996-03-28
CN1057095C (zh) 2000-10-04
EP0674652B1 (de) 2000-09-13
NO952366D0 (no) 1995-06-15
IL107987A (en) 1999-10-28
WO1994013695A1 (en) 1994-06-23
AU679479B2 (en) 1997-07-03
SI9300661A (en) 1994-06-30

Similar Documents

Publication Publication Date Title
DE69329425D1 (de) Dolastatin analog
MY124487A (en) Dolastatin derivatives, their preparation and use
DK0642530T3 (da) Dolastatinderivater
MX9203100A (es) Nuevos peptidos, su preparacion y su aplicacion.
ES460620A1 (es) Procedimiento para la preparacion de peptidos y derivados depeptidos.
NO954328L (no) Nye substituerte 1-fenyl-pyridinyl-benzotriazoler
ES2098338T3 (es) Heteroarilmetilbencenos.
DK242089D0 (da) Anvendelse af pyrimido oe6,1-aaa-isoquinolin-4-on-derivater til hindring af haaraffald og foroegelse af haarvaekst
MY114327A (en) Novel peptides, the preparation and use thereof
FR2657879B1 (fr) Plaque de culture cellulaire.
MX9800053A (es) Herbicidas de cis-2,3-expoxicicloalcanol bencilado.
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee